Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Liver Diseases

  Free Subscription


5 AJR Am J Roentgenol
1 Am J Pathol
5 Biochem Biophys Res Commun
6 BMC Cancer
1 BMC Gastroenterol
1 Br J Surg
5 Eur Radiol
1 Gastroenterology
3 Gut
17 Hepatology
1 Int J Cancer
2 J Gastroenterol Hepatol
15 J Hepatol
1 Oncogene
1 PLoS One
2 Radiology
2 Semin Liver Dis
2 Transplant Proc
6 Transplantation

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. HUBER AT, Obmann V
    Beyond the AJR: Prognostic Value of a Single Baseline Liver Stiffness Measurement by MR Elastography in Patients With Chronic Liver Disease.
    AJR Am J Roentgenol. 2022;219:169.

  2. YOUNG S
    Editorial Comment: Echocardiography-Should It Be Routine Before Elective TIPS?
    AJR Am J Roentgenol. 2022 Mar 2. doi: 10.2214/AJR.22.27580.

    Editorial Comment: LI-RADS Provides High Accuracy for Liver Transplant Eligibility in High-Risk Patients.
    AJR Am J Roentgenol. 2022;219:96.

  4. GEE MS
    Editorial Comment: Novel Associations Between Quantitative MRI Metrics and Clinical Risk Scores in Young Patients With Autoimmune Liver Disease.
    AJR Am J Roentgenol. 2022 Feb 2. doi: 10.2214/AJR.22.27453.

  5. MCCRARY J, Trout AT, Mahalingam N, Singh R, et al
    Associations Between Quantitative MRI Metrics and Clinical Risk Scores in Children and Young Adults With Autoimmune Liver Disease.
    AJR Am J Roentgenol. 2022 Jan 26. doi: 10.2214/AJR.21.27204.
    PubMed         Abstract available

    Am J Pathol

  6. ROY N, Alencastro F, Roseman BA, Wilson SR, et al
    Dysregulation of Lipid and Glucose Homeostasis in Hepatocyte-Specific SLC25A34 Knockout Mice.
    Am J Pathol. 2022 Jun 16. pii: S0002-9440(22)00172.
    PubMed         Abstract available

    Biochem Biophys Res Commun

  7. SAKURAI M, Weber P, Wolff G, Wieder A, et al
    TSC22D4 promotes TGFbeta1-induced activation of hepatic stellate cells.
    Biochem Biophys Res Commun. 2022;618:46-53.
    PubMed         Abstract available

  8. WU W, Lu P, Huang Y, Zhu Z, et al
    Emodin regulates the autophagy via the miR-371a-5p/PTEN axis to inhibit hepatic malignancy.
    Biochem Biophys Res Commun. 2022;619:1-8.
    PubMed         Abstract available

  9. JUNG SY, Yun HH, Lim JH, Lee DH, et al
    Hepatocyte-specific deletion of Bis causes senescence in the liver without deteriorating hepatic function.
    Biochem Biophys Res Commun. 2022;619:42-48.
    PubMed         Abstract available

  10. LI S, Wang Y, Dun W, Han W, et al
    Phosphoproteomic analysis of FAC overload-triggered human hepatic cells reveals G2/M phase arrest.
    Biochem Biophys Res Commun. 2022;619:62-67.
    PubMed         Abstract available

  11. PEI Y, Balogun O, Otieno D, Parks JS, et al
    The effects of brewers' spent grain on high-fat diet-induced fatty liver.
    Biochem Biophys Res Commun. 2022;616:49-55.
    PubMed         Abstract available

    BMC Cancer

  12. YAMAGUCHI F, Hirata Y, Akram H, Kamitori K, et al
    Editorial Expression of Concern: FOXO/TXNIP pathway is involved in the suppression of hepatocellular carcinoma growth by glutamate antagonist MK-801.
    BMC Cancer. 2022;22:665.

  13. GUADAGNI S, Masedu F, Fiorentini G, Sarti D, et al
    Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver
    BMC Cancer. 2022;22:660.
    PubMed         Abstract available

  14. JIANG AN, Wang B, Wang S, Zhao K, et al
    The study of direct and indirect effects of radiofrequency ablation on tumor microenvironment in liver tumor animal model.
    BMC Cancer. 2022;22:663.
    PubMed         Abstract available

  15. QIN B, Zeng Z, Xu J, Shangwen J, et al
    Emodin inhibits invasion and migration of hepatocellular carcinoma cells via regulating autophagy-mediated degradation of snail and beta-catenin.
    BMC Cancer. 2022;22:671.
    PubMed         Abstract available

  16. LI N, Wan X, Zhang H, Zhang Z, et al
    Tumor and peritumor radiomics analysis based on contrast-enhanced CT for predicting early and late recurrence of hepatocellular carcinoma after liver resection.
    BMC Cancer. 2022;22:664.
    PubMed         Abstract available

  17. HUANG WJ, Wang GY, Liu ZY, Zhang ML, et al
    Preoperative PDW levels predict pulmonary metastasis in patients with hepatocellular carcinoma.
    BMC Cancer. 2022;22:683.
    PubMed         Abstract available

    BMC Gastroenterol

  18. HAN D, Zhang H, Liu S, Zhuang L, et al
    Association between the LRP5 rs556442 gene polymorphism and the risks of NAFLD and CHD in a Chinese Han population.
    BMC Gastroenterol. 2022;22:305.
    PubMed         Abstract available

    Br J Surg

  19. SHEN Q, Li T, Zhou J
    Comment on: Early postoperative arterial lactate concentrations to stratify risk of post-hepatectomy liver failure.
    Br J Surg. 2022;109:e85.

    Eur Radiol

  20. CHOI SJ, Choi SH, Lee DY, Lee JS, et al
    Diagnostic value of [(68) Ga]Ga-DOTA-labeled-somatostatin analogue PET/MRI for detecting liver metastasis in patients with neuroendocrine tumors: a systematic review and meta-analysis.
    Eur Radiol. 2022;32:4628-4637.
    PubMed         Abstract available

  21. DIMOV IP, Tous C, Li N, Barat M, et al
    Assessment of hepatic arterial hemodynamics with 4D flow MRI: in vitro analysis of motion and spatial resolution related error and in vivo feasibility study in 20 volunteers.
    Eur Radiol. 2022 Jun 22. pii: 10.1007/s00330-022-08890.
    PubMed         Abstract available

  22. KENNEDY P, Stocker D, Carbonell G, Said D, et al
    MR elastography outperforms shear wave elastography for the diagnosis of clinically significant portal hypertension.
    Eur Radiol. 2022 Jun 21. pii: 10.1007/s00330-022-08935.
    PubMed         Abstract available

  23. HWANG JA, Jeong WK, Kang HJ, Lee ES, et al
    Perfluorobutane-enhanced ultrasonography with a Kupffer phase: improved diagnostic sensitivity for hepatocellular carcinoma.
    Eur Radiol. 2022 Jun 16. pii: 10.1007/s00330-022-08900.
    PubMed         Abstract available

  24. JIAO CY, Zhang H, Ji GW, Xu Q, et al
    CT-based clinico-radiological nomograms for prognosis prediction in patients with intrahepatic mass-forming cholangiocarcinoma: a multi-institutional study.
    Eur Radiol. 2022 Jun 16. pii: 10.1007/s00330-022-08914.
    PubMed         Abstract available


  25. YING X, Rosenblatt R, Fortune BE
    Trends in Industry Payments to Gastroenterologists and Hepatologists in the United States from 2014 to 2020.
    Gastroenterology. 2022 Jun 14. pii: S0016-5085(22)00647.


    Transcription factor p63, a member of the p53 family of tumour suppressors, regulates hepatic glucose metabolism.
    Gut. 2022 Jun 15. pii: gutjnl-2022-327790. doi: 10.1136/gutjnl-2022-327790.

  27. AWONIYI M, Wang J, Ngo B, Meadows V, et al
    Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC.
    Gut. 2022 Jun 15. pii: gutjnl-2021-326500. doi: 10.1136/gutjnl-2021-326500.
    PubMed         Abstract available

  28. BEA S, Jeong HE, Park S, Yu OHY, et al
    Hepatic events associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a nationwide cohort study.
    Gut. 2022 Jun 20. pii: gutjnl-2022-327504. doi: 10.1136/gutjnl-2022-327504.


  29. JOHN BV, Doshi A, Ferreira RD, Taddei TH, et al
    Comparison of Infection-induced and Vaccine-induced Immunity Against Coronavirus 2019 in Patients with Cirrhosis.
    Hepatology. 2022 Jun 16. doi: 10.1002/hep.32619.
    PubMed         Abstract available

  30. YUAN T, Zhou T, Qian M, Du J, et al
    SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ.
    Hepatology. 2022 Jun 17. doi: 10.1002/hep.32621.
    PubMed         Abstract available

  31. POVERO D, Ahn JC, Arnold J, Udompap P, et al
    Hepatology Highlights.
    Hepatology. 2022;76:1-2.

  32. ZHAO K, Guo F, Wang J, Zhong Y, et al
    Limited disassembly of cytoplasmic hepatitis B virus nucleocapsids restricts viral infection in murine hepatic cells.
    Hepatology. 2022 Jun 19. doi: 10.1002/hep.32622.
    PubMed         Abstract available

  33. DEVARAJ E, Perumal E, Subramaniyan R, Mustapha N, et al
    Liver fibrosis: Extracellular vesicles mediated intercellular communication in perisinusoidal space.
    Hepatology. 2022;76:275-285.

  34. STINE JG, Schreibman IR, Faust AJ, Dahmus J, et al
    NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH.
    Hepatology. 2022;76:172-185.
    PubMed         Abstract available

  35. KAWAMURA N, Imajo K, Kalutkiewicz KJ, Nagai K, et al
    Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.
    Hepatology. 2022;76:186-195.
    PubMed         Abstract available

  36. LEWIS JH
    Digitizing DILI: Who can? RUCAM? RECAM?
    Hepatology. 2022;76:3-5.

  37. SERPER M, Parikh ND, Thiele G, Ovchinsky N, et al
    Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
    Hepatology. 2022;76:251-274.
    PubMed         Abstract available

  38. HAYASHI PH, Lucena MI, Fontana RJ, Bjornsson ES, et al
    A revised electronic version of RUCAM for the diagnosis of DILI.
    Hepatology. 2022;76:18-31.
    PubMed         Abstract available

    Microwave ablation in skilled hands. A treatment opportunity gaining room in the field of single HCC 3-5 cm.
    Hepatology. 2022;76:6-8.

  40. KAPPUS MR, Patel YA, Duarte-Rojo A
    Improving the fitness of the NASH clinical trial: Standardizing the standard-of-care intervention.
    Hepatology. 2022;76:12-14.

  41. TAO X, Zhao Y, Chen L, Zeng M, et al
    Letter to the editor: Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter study.
    Hepatology. 2022;76:E13-E14.

  42. KIVLIGHN S, Schuur E, Gish RG, Cryer D, et al
    Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol-associated liver disease need our attention.
    Hepatology. 2022;76:E7-E8.

  43. RASCHI E, Caraceni P
    Letter to the editor: RECAM for the diagnosis of DILI-Is it time to incorporate additional pharmacological criteria?
    Hepatology. 2022;76:E25-E26.

  44. DANAN G, Teschke R
    Letter to the editor: Electronic RUCAM: Major pitfalls call for caution and proper validation.
    Hepatology. 2022;76:E27.

  45. RYDELL GE, Ringlander J, Larsson SB, Hellstrand K, et al
    Letter to the editor: Alu-PCR design may have compromised detection of integrated core HBV DNA.
    Hepatology. 2022;76:E23.

    Int J Cancer

  46. NIGER M, Nichetti F, Casadei-Gardini A, Rizzato MD, et al
    Platinum sensitivity in patients with IDH1/2 mutated versus wild-type intrahepatic cholangiocarcinoma: a propensity score-based study.
    Int J Cancer. 2022 Jun 20. doi: 10.1002/ijc.34182.
    PubMed         Abstract available

    J Gastroenterol Hepatol

  47. WONG YJ, Li J, Liu C, Chen Z, et al
    CHESS-ALARM score to stratify decompensation risk in compensated advanced chronic liver disease patients: An international multicenter study.
    J Gastroenterol Hepatol. 2022;37:1043-1051.
    PubMed         Abstract available

  48. LIU H, Yang XL, Dong ZR, Chen ZQ, et al
    Clinical Benefits of Direct-acting Antivirals Therapy in Hepatitis C Virus Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
    J Gastroenterol Hepatol. 2022 Jun 20. doi: 10.1111/jgh.15915.
    PubMed         Abstract available

    J Hepatol

  49. JOHANSEN S, Thiele M, Juel HB, Hansen T, et al
    External validation of a genetic risk score that predicts development of alcohol-related cirrhosis.
    J Hepatol. 2022 Jun 13. pii: S0168-8278(22)00365.

  50. SALEM R, Tselikas L, De Baere T
    Interventional treatment of hepatocellular carcinoma.
    J Hepatol. 2022 Jun 12. pii: S0168-8278(22)00229.

  51. LURZ E, Lenz D, Bufler P, Fichtner A, et al
    Letter to the editor - A peditatric hepatologists' perspective.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00363.

  52. BRESCIANI N, Demagny H, Lemos V, Pontanari F, et al
    SLC25A47 is a novel determinant of hepatic mitochondrial function implicated in liver fibrosis.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00364.
    PubMed         Abstract available

  53. SCHLEGEL A, Porte RJ, Dutkowski P
    Corrigendum to 'Protective mechanisms and current clinical evidence of hypothermic oxygenated machine perfusion (HOPE) in preventing post-transplant cholangiopathy' [J Hepatol 76 (2022) 1330-1347].
    J Hepatol. 2022 Jun 16. pii: S0168-8278(22)00353.

  54. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy.
    J Hepatol. 2022 Jun 7. pii: S0168-8278(22)00346.

  55. BEAUFRERE A, Vilgrain V, Paradis V
    Reply to chao Li et al., Zi-Xiang Chen et al. and Ke-Chun Wang et al.: "Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies".
    J Hepatol. 2022 Jun 19. pii: S0168-8278(22)00374.

  56. JEPSEN P, Reeves H
    Signed, SEALed, detected I'm your patient with advanced fibrosis or cirrhosis!
    J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00369.

  57. ALVISI G, Termanini A, Soldani C, Portale F, et al
    Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
    J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00370.
    PubMed         Abstract available

  58. MENDEZ-SANCHEZ N, Maris-Gil S, Alonso-Rivera CG
    Latin American Association of Pediatrics (ALAPE) endorses the MAFLD definition of fatty liver disease.
    J Hepatol. 2022;77:249.

  59. CHEN YS, Hung YM, Wei JC
    Comment on "Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease".
    J Hepatol. 2022;77:259-260.

  60. MARTI-AGUADO D, Clemente-Sanchez A, Bataller R
    Cigarette smoking and liver diseases.
    J Hepatol. 2022;77:191-205.
    PubMed         Abstract available

  61. YU M, Chen Z, Zhou Q, Zhang B, et al
    PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy.
    J Hepatol. 2022;77:140-151.
    PubMed         Abstract available

  62. GUO B, Zhou J, Zhao X
    Reply to: "Comment on "Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease"".
    J Hepatol. 2022;77:260-262.

    Revealing anti-PD-1 resistance mechanisms in HCC: A path towards novel combination immunotherapies.
    J Hepatol. 2022;77:9-11.


  64. WANG Y, Zhang Y, Mi J, Jiang C, et al
    ANKFN1 plays both protumorigenic and metastatic roles in hepatocellular carcinoma.
    Oncogene. 2022 Jun 21. pii: 10.1038/s41388-022-02380.
    PubMed         Abstract available

    PLoS One

  65. KOGISO T, Sagawa T, Taniai M, Shimada E, et al
    Risk factors for Fontan-associated hepatocellular carcinoma.
    PLoS One. 2022;17:e0270230.
    PubMed         Abstract available


  66. JANG JK, Lee ES, Seo JW, Kim YR, et al
    Two-dimensional Shear-Wave Elastography and US Attenuation Imaging for Nonalcoholic Steatohepatitis Diagnosis: A Cross-sectional, Multicenter Study.
    Radiology. 2022 Jun 21:220220. doi: 10.1148/radiol.220220.
    PubMed         Abstract available

  67. JUNG J, Han A, Madamba E, Bettencourt R, et al
    Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD.
    Radiology. 2022 Mar 29:211131. doi: 10.1148/radiol.211131.
    PubMed         Abstract available

    Semin Liver Dis

  68. GRINSPAN LT, Villanueva A
    Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma.
    Semin Liver Dis. 2022;42:188-201.
    PubMed         Abstract available

  69. CHEW N, Ng CH, Truong E, Noureddin M, et al
    Non-Alcoholic Steatohepatitis Drug Development Pipeline: An Update.
    Semin Liver Dis. 2022 Jun 16. doi: 10.1055/a-1877-9656.
    PubMed         Abstract available

    Transplant Proc

  70. ROMERES SGB, Trevizoli NC, Oliveira CAM, Obeid EJ, et al
    Progressive Familial Intrahepatic Cholestasis Type 2 and Recurrence After Liver Transplantation: A Case Report.
    Transplant Proc. 2022 Jun 16. pii: S0041-1345(22)00271.
    PubMed         Abstract available

  71. DALA RIVA DF, Nacif LS, Fernandes MR, Silva NA, et al
    Relationship of Anatomic Variations and Arterial Reconstruction of the Hepatic Artery: Prevalence and Effect on Orthotopic Liver Transplantation.
    Transplant Proc. 2022 Jun 15. pii: S0041-1345(22)00270.
    PubMed         Abstract available


  72. PERKONS NR, Metz DC, Siegelman ES, Yang Z, et al
    Where LI-RADS Falls Short: Two Cases of Image-diagnosed HCC, Found to Be NET on Explant.
    Transplantation. 2022;106:e350-e351.

  73. LEE EJ, Sood V, Raghu V, Squires J, et al
    Liver Transplantation From a Heterozygous Living-related Donor Into an Alpha-1 Antitrypsin Deficient Pediatric Recipient.
    Transplantation. 2021;105.

  74. BLACK K, Ziogas IA, Thurm C, Hall M, et al
    Pediatric Liver Transplant Outcomes in Alagille Syndrome: A Linked Database Analysis.
    Transplantation. 2021;105.

  75. ANTALA S, Godown J, Neighbors K, Thurm C, et al
    Multi-center Study of Peri-transplant Outcomes for Acute Liver Failure in Neonates Compared to Older Infants.
    Transplantation. 2021;105.

    Commentary on Rising Trend in Waitlisting for Alcoholic Hepatitis With More Favorable Outcomes Than Other High Model for End-stage Liver Disease in the Current Era.
    Transplantation. 2022 Mar 24. pii: 00007890-900000000-95040.

  77. IVANICS T, Wallace D, Abreu P, Claasen MP, et al
    Survival After Liver Transplantation: An International Comparison Between the United States and the United Kingdom in the Years 2008-2016.
    Transplantation. 2021 Nov 9. pii: 00007890-900000000-95135.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.